Denali Therapeutics Inc
DNLI
Market Cap$2.75B
Close$
$21.82
18.2% upside
Current Fair Value
18.2% upsideUndervalued by 18.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.75 Billion |
|---|---|
| Enterprise Value | $1.81 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-0.98 |
| Beta | 2.17 |
| Outstanding Shares | 142,609,036 |
| Avg 30 Day Volume | 1,021,334 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -20.01 |
|---|---|
| PEG | 275.35 |
| Price to Sales | 9.23 |
| Price to Book Ratio | 1.85 |
| Enterprise Value to Revenue | 6.13 |
| Enterprise Value to EBIT | -8.7 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Denali Therapeutics Inc
CEO: Ryan Watts